Daily Financial Update
Market Pulse: Global markets drifted into the holiday session on edge after a blockbuster Infosys ADR short squeeze triggered a trading halt and biotech bulls celebrated the FDA green light for MYQORZO™.
Key Movers: Infosys ADRs, Cytokinetics’ FDA approval saga, and a potential BP-Shell megadeal chatter have traders glued to their screens.
Macro & Politics: Regulators are on high alert—from anti-trust hawks eyeing the BP and Shell rumors to ethics probes around ex-FDA chiefs taking COVID-vax lobbying cash.
What’s Next: Keep a tab on biotech mini-conferences for fresh FDA cues and BP’s next strategic update.
Market Commentary
Everyone’s glossing over the fact that a holiday thin market just amplified that Infosys ADR rip to 40%, as detailed in “Explainer: Why Infosys ADRs jumped 40% and why the NYSE halted trading” (The Times of India). When volumes evaporate, algos and manual squeezes carve up traders with minimal warning—there’s a real threat of false signals itching to blow up in your face.
Don’t overlook how ethics storms in Washington, sparked by “In cahoots: Ex-FDA commissioners against higher vaccine standards took $6 million from COVID vax makers” (Wnd.com), could bleed into biotech prices like Cytokinetics’ post-approval rally. When regulators swap pharma for politics, you get cross-sector ripples—biotech bulls might find the FDA cadence disrupted just as energy deal chatter heats up.
Here’s the play: lighten up on illiquid corporate names heading into year-end, watch the docket for the next FDA rulings, and position for the BP-Shell saga—any anti-trust tweak could be the mother of all catalysts. Keep your scans tight or expect to get screwed.
📈 Breaking Financial News
Explainer: Why Infosys ADRs jumped 40% and why the NYSE halted trading
Infosys ADRs surged 40% on the NYSE, hitting a 52-week high of $30 and triggering two trading halts. Analysts cite a combination of a short squeeze, automated trading glitches, and low holiday liquidity. Infosys clarified there were no material developments b…
Cytokinetics Announces FDA Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Funct
Cytokinetics Announces FDA Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and SymptomsCytokinetics Cytokinetics heart drug wins FDA approval, the biotech’s fi…
Cytokinetics announces FDA approval of Myqorzo
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of…
Novo submits its next-gen obesity drug for FDA approval
Novo Nordisk has filed for FDA approval of its next-generation, combination obesity drug, CagriSema, with a review expected next year.
Oil Jumps 8.5% on Middle East Crisis Oil surged 8.5% to $74/barrel after Israel'
Experts predict $100+ oil if conflict spreads. Don't chase volatile oil stocks. See Marc's safer alternative here
🔍 Market Analysis & Insights
Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season
MEDVi lists compounded GLP-1 injections at $179 first month, $299 refills as 100,000+ patients seek affordable semaglutide ahead of 2026 New Year….
BP CEO Shake-Up Reopens Talk of a Shell Megadeal
The appointment of Meg O’Neill as BP's chief executive officer, replacing Murray Auchincloss, is a momentous milestone in the oil industry. When O’Neill takes over on April 1, 2026, she will become the first woman ever to lead a Big Oil company. But O’Neill’s…
In cahoots: Ex-FDA commissioners against higher vaccine standards took $6 million from COVID vax makers
‘Old guard' bashed Trump appointees for expecting most new approvals will need randomized clinical trials
Other Barks and Bites for Friday, December 19: UK High Court Defines Scope of RAND Obligations; Senators Welch and Blackburn Introduce Copyright Reform Bill; and Global Value of Music Copyright Doubles Since 2015
This week in Other Barks and Bites: Will Page’s Global Value of Music Copyright report shows that industry revenues have doubled since 2015 despite slowing growth as pandemic impacts are no longer felt; the Federal Circuit rules that it lacks jurisdiction to …
Decrypt’s 2025 Project of the Year: Hyperliquid
Hyperliquid, a venue for high-risk leveraged trading on volatile assets, captured the attention of the crypto industry like no other project this year.
EXPERT: ” Every American Investor Could Soon Become a Millionaire” Imagine a bul
Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: “Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you.” This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story.
💰 Investment Opportunities
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 comm…
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Financing included participation by healthcare-dedicated investors alongside existing shareholders Financing included participation by healthcare-dedicated investors alongside existing shareholders
Terence Corcoran: Markets still prevail, from EVs to Anglo-Teck
In a global world seemingly dominated by state capitalism, there are developments that suggest markets still prevail. Read more.
Presentation: Lessons Learned From Shipping AI-Powered Healthcare Products
Clara Matos discusses the journey of shipping AI-powered healthcare products at Sword Health. She explains how to implement input/output guardrails for regulated industries and shares a framework for robust evaluations using human and LLM-based ratings. From …
Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®
According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth quarter of 2026, or earlier under certain circumstances REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, …